CNBC·
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
Summary
- Hims & Hers Health announced the rollout of five compounded peptide and longevity formulations in the U.S. under its Peptides+ platform, none of which are approved by regulators.
- The company acknowledged uncertainty regarding the optimal usage & effectiveness of the peptides while noting that federal restrictions on compounding certain unapproved peptides were recently eased.
- More than 10,000 people signed up for an early access list within 15 days of its launch in late October.
- Specific products include compounded sermorelin, glutathione, NAD+, vitamin B-12, & L-carnitine, all formulated by licensed pharmacies adhering to state quality standards.
- Future offerings may include unapproved peptides BPC-157 & TB-500, most research on which has been conducted in animals rather than humans.
- Patients must undergo a health history assessment with a licensed provider to receive a personalized plan, with ongoing monitoring & dose adjustments managed through the platform.
- Individuals with serious illnesses such as cardiovascular, liver, or kidney disease are currently excluded from receiving these compounds.
- Andrew Huberman, a new board member, described the compounds as real medical treatments supported by trusted sourcing & physician oversight.
- Health experts warn that the lack of rigorous human trials means serious risks, including rare complications & immune responses, cannot be ruled out.
- Experts state that dosing for these products is not established, making it difficult to determine effective amounts versus risky levels.
- Hims offers a Care+ program including twice-a-year lab testing & 24/7 messaging with providers trained in peptide therapy.
- Critics argue that online-only physician supervision is insufficient for prescribing unapproved medications.
- The HHS issued a policy in October stating the FDA will not enforce action against pharmacies compounding six specific unapproved peptides while formal rules are reviewed.
- This policy follows a 2023 FDA restriction on compounding due to safety & impurity concerns & aligns with HHS Secretary Robert F. Kennedy Jr.'s support for broader peptide access.
- Hims acquired a California-based peptide manufacturing facility in February 2025 to support production.
- A 2026 systematic review found zero eligible clinical trials proving IV or intramuscular NAD+ improves anti-aging, energy, or wellness endpoints in humans.
- Reviews of L-carnitine trials show an average weight loss of 2.7 pounds, though this does not confirm efficacy for compounded injections.
- Vitamin B-12 injections are primarily used for diagnosed deficiencies, which affect only 3.6% of U.S. adults.
- Evidence for glutathione's skin-whitening claims is thin, with studies showing limited effectiveness & a loss of efficacy over time.
- The FDA received reports of at least 30 adverse events linked to compounded IV glutathione, including recalls for elevated endotoxin levels in products from a single wholesale distributor.
The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
- Keywords
- Health care industry,Breaking News: Politics,Politics,United States,Hims & Hers Health Inc,Medication,Science,State Street SPDR S&P Health Care Equipment ETF,SPDR S&P Health Care Services ETF,iShares U.S. Healthcare ETF,ARK Genomic Revolution ETF,business news